|
|
|
|
Effective July 1, 2023 the new Healthcare Common Procedure Coding System (HCPCS) J-Code for panzyga will be J1576 (Injection, immune globulin [panzyga], intravenous, non-lyophilized [e.g., liquid], 500 mg).
|
|
|
- Until July 1, 2023, customers are advised to continue using current HCPCS code J1599
- All pending claims with date of service prior to July 1, 2023 submitted for reimbursement after the effective date should still be submitted with HCPCS code J1599
|
|
|
|
|
|
|
For questions or reimbursement support, please contact the Octapharma reimbursement team.
|
|
|
|
|
|
|
|
|
|
INDICATIONS AND USAGEPanzyga (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older, for chronic immune thrombocytopenia (cITP) in adults, and for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.ContraindicationsPanzyga is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.
|
|
|
WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILUREPlease see full Prescribing Information, including BOXED WARNING.
- Thrombosis may occur with immune globulin intravenous (IGIV) products, including panzyga. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
- Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including panzyga. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Panzyga does not contain sucrose.
- For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer panzyga at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2, 5.4)]
|
|
|
|
|
|
|
|
|
